Intercept Pharma's hopes of getting its non-alcoholic steatohepatitis (NASH) therapy obeticholic acid (OCA) in the US may have taken another dive, after it flunked a phase 3 trial. Shares in the ...

Ocaliva (obeticholic acid) is a prescription drug that’s used to treat primary biliary cholangitis (PBC). Ocaliva comes as an oral tablet. Ocaliva is used to treat primary biliary cholangitis ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

Intercept Pharma’s obeticholic acid (OCA) – trying to become the first FDA-approved therapy for non-alcoholic steatohepatitis (NASH) – will come under scrutiny by FDA advisors before the ...

原发性胆汁性胆管炎（primary biliary cholangitis,PBC）是一种慢性自身免疫性肝内胆汁淤积性疾病，多见于中老年女性，早期可无症状，临床常见为乏力和皮肤瘙痒等症状。疾病的早期识别和及时治疗对其预后非常重要。本文介绍了PBC的诊疗要点，以供参考。

Licensed therapies include ursodeoxycholic acid (UDCA) and obeticholic acid (OCA), alongside experimental new and re-purposed agents. Disease management focuses on initiation of UDCA for all patients ...

In June 2023, the US Food and Drug Administration (FDA) rejected Intercept Pharmaceuticals’ new drug application (NDA) for ...

Terns Pharmaceuticals' TERN-701 and TERN-601 face challenges in CML and obesity. Find out why TERN stock is not a strong buy amid tough competition.